Video

Discussing Genetic Testing in Colorectal Cancer

Understanding the genetics of colorectal cancer can help determine an optimal treatment strategy, making it important to have a detailed discussion with patients regarding the value of genetic testing, states Tanios Bekaii-Saab, MD. The concept of genetic testing should be introduced during initial treatment discussions or as a follow-up discussion, Bekaii-Saab advises.

Proper communications regarding mutations as drivers of cancer growth is important, says Saab. There may be available treatments that can target these drivers and inhibit the growth and spread of disease. It is also important to distinguish between the genetics of the tumor and the patient’s own genetics.

Terminology, such as RAS mutations and microsatellite instability, can complicate discussions with patients, says John L. Marshall, MD. In order to clearly present complex information to patients, it is important for clinicians themselves to be informed regarding all aspects of the disease and its management, adds Marshall.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.